Agouti-related peptide and MC3/4 receptor agonists both inhibit excitatory hypothalamic ventromedial nucleus neurons

J Neurosci. 2008 May 21;28(21):5433-49. doi: 10.1523/JNEUROSCI.0749-08.2008.

Abstract

Anorexigenic melanocortins decrease food intake by activating MC3/MC4 receptors (MC3/4R); the prevailing view is that the orexigenic neuropeptide agouti-related peptide (AgRP) exerts the opposite action by acting as an antagonist at MC3/MC4 receptors. A total of 370 hypothalamic ventromedial nucleus (VMH) glutamatergic neurons was studied using whole-cell recording in hypothalamic slices from a novel mouse expressing green fluorescent protein (GFP) under control of the vesicular glutamate transporter 2 (vGluT2) promoter. Massive numbers of GFP-expressing VMH dendrites extended out of the core of the nucleus into the surrounding cell-poor shell. VMH dendrites received frequent appositions from AgRP-immunoreactive axons in the shell of the nucleus, but not the core, suggesting that AgRP may influence target VMH neurons. alpha-MSH, melanotan II (MTII), and selective MC3R or MC4R agonists were all inhibitory, reducing the spontaneous firing rate and hyperpolarizing vGluT2 neurons. The MC3/4R antagonist SHU9119 was excitatory. Unexpectedly, AgRP did not attenuate MTII actions on these neurons; instead, these two compounds showed an additive inhibitory effect. In the absence of synaptic activity, no hyperpolarization or change in input resistance was evoked by either MTII or AgRP, suggesting indirect actions. Consistent with this view, MTII increased the frequency of spontaneous and miniature IPSCs. In contrast, the mechanism of AgRP inhibition was dependent on presynaptic inhibition of EPSCs mediated by G(i)/G(o)-proteins, and was attenuated by pertussis toxin and NF023, inconsistent with mediation by G(s)-proteins associated with MC receptors. Together, our data suggest that the mechanism of AgRP actions on these excitatory VMH cells appears to be independent of the actions of melanocortins on MC receptors.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Agouti-Related Protein / pharmacology*
  • Analysis of Variance
  • Animals
  • Axons / metabolism
  • Dose-Response Relationship, Radiation
  • Electric Stimulation / methods
  • Excitatory Amino Acid Agonists / pharmacology
  • Excitatory Amino Acid Antagonists / pharmacology
  • GABA Agonists / pharmacology
  • Glucose Transporter Type 2 / metabolism
  • Glutamate Decarboxylase / metabolism
  • Green Fluorescent Proteins / biosynthesis
  • Green Fluorescent Proteins / genetics
  • In Vitro Techniques
  • Melanocyte-Stimulating Hormones / pharmacology
  • Membrane Potentials / drug effects
  • Membrane Potentials / physiology
  • Membrane Potentials / radiation effects
  • Mice
  • Mice, Transgenic
  • Muscimol / pharmacology
  • Neural Inhibition / drug effects*
  • Neurons / cytology
  • Neurons / drug effects*
  • Neuropeptide Y / pharmacology
  • Patch-Clamp Techniques / methods
  • Receptor, Melanocortin, Type 3 / agonists*
  • Receptor, Melanocortin, Type 3 / antagonists & inhibitors
  • Ventromedial Hypothalamic Nucleus / cytology*
  • Vesicular Glutamate Transport Protein 2 / genetics
  • alpha-MSH / analogs & derivatives*
  • alpha-MSH / pharmacology

Substances

  • Agouti-Related Protein
  • Excitatory Amino Acid Agonists
  • Excitatory Amino Acid Antagonists
  • GABA Agonists
  • Glucose Transporter Type 2
  • Neuropeptide Y
  • Receptor, Melanocortin, Type 3
  • Slc17a6 protein, mouse
  • Slc2a2 protein, mouse
  • Vesicular Glutamate Transport Protein 2
  • acetyl-norleucyl(4)-(aspartyl(5)-histidyl(6)-phenylalanyl(7)-arginyl(8)-tryptophyl(9)-lysyl(10))cyclo-alpha-MSH(4-10)amide
  • Green Fluorescent Proteins
  • SHU 9119
  • Muscimol
  • alpha-MSH
  • Melanocyte-Stimulating Hormones
  • Glutamate Decarboxylase
  • glutamate decarboxylase 1